Could T-cell immunotherapy be the answer to COVID-19?
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
List view / Grid view
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
Researchers have created a new kind of immunotherapy using the interleukin-27 (IL-27) cytokine to effectively combat tumours in vitro and in vivo.
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.
Researchers have developed a new CAR T-cell therapy that targets an antigen called glycipan-1 (GPC1), showing efficacy at fighting solid tumours in mice.
A new study has shown that the role of T cell-suppressing dendritic cells can be reversed in mice, indicating that immunotherapies could be improved with this method.
Researchers observed that deleting the IRE1-alpha gene caused beta cells to de-differentiate and then re-differentiate in mice, preventing immune system auto-activation.
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
More research into tuberculosis is now possible with the development of an optimisied mouse model that exhibits the same blood immune response to Mycobacterium tuberculosis infection as humans.
Researchers have shown that natural killer (NK) cells work best as an immunotherapy when in an early stage of development, so could be manufactured from pluripotent stem cells.
Identifying next generation targets for cancer immunotherapy.
Using nuclear magnetic resonance spectroscopy, a study has shown that IL-2 can stimulate both effector T cells and regulatory T cells by adopting different structural forms.
Multiple co-signalling molecules regulate T cell activation.